Last reviewed · How we verify
NCT03253003
Quality Control of CE-Certified Phonak Hearing Aids - 2017_27
NA trial testing Line extension of the Phonak Audéo B product family in Hearing Loss, Bilateral Sensorineural, Progressive in 19 participants. Completed in 25 August 2017.
25 August 2017
Quick facts
| Lead sponsor | Sonova AG |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 19 |
| Start date | 7 August 2017 |
| Primary completion | 25 August 2017 |
| Estimated completion | 25 August 2017 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Line extension of the Phonak Audéo B product family
Conditions studied
- Hearing Loss, Bilateral Sensorineural, Progressive — all drugs for Hearing Loss, Bilateral Sensorineural, Progressive →
Sponsor
Sonova AG — full company profile →
Who can join
Adults 18 to 99, any sex, with Hearing Loss, Bilateral Sensorineural, Progressive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of participants with a hearing loss to grant quality control prior to product launch. The aim of the investigation series is to ensure a stable overall performance of the new hearing systems, a good sound quality during phone calls as well as maximum benefit for the participant with the devices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03253003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Line extension of the Phonak Audéo B product family
Trials testing the same drug.
- NCT03131557 — Quality Control of CE-Certified Phonak Hearing Aids - 2017_13 · NA · completed
Other Sonova AG trials
Trials by the same sponsor.
- NCT07526428 — Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment · NA · enrolling by invitation
- NCT07501312 — Remote Microphone Performance Comparison in Adults With Hearing Loss · NA · enrolling by invitation
- NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
- NCT06957730 — A Comparison of Hearing Aid Noise Programs on Speech Intelligibility · NA · completed
- NCT06746038 — Evaluation of Extended Wear Hearing Aid for Mild Hearing Loss · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03253003 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sonova AG
- Last refreshed: 25 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03253003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing